Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50902
Name medulloblastoma
Definition An infratentorial cancer that is located_in the lower part of the brain and is a type of primitive neuroectodermal tumor.
Source DiseaseOntology.org
Alt Ids DOID:4981 DOID:168 DOID:0060105 DOID:3858
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer brain cancer infratentorial cancer medulloblastoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
SMO wild-type Taladegib medulloblastoma sensitive detail...
SMO W535L Arsenic trioxide medulloblastoma sensitive detail...
RB1 positive Palbociclib medulloblastoma sensitive detail...
Unknown unknown M344 medulloblastoma not applicable detail...
Unknown unknown Prexasertib medulloblastoma not applicable detail...
EZH2 over exp MC3629 medulloblastoma predicted - sensitive detail...
CTNNB1 mutant N/A medulloblastoma not applicable detail...
APC mutant N/A medulloblastoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00089245 Phase I Omburtamab I-131 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Active, not recruiting
NCT00601003 Phase II Cyclophosphamide + Nifurtimox + Topotecan Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Active, not recruiting
NCT00602667 Phase I Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting
NCT00876993 Phase I Bevacizumab + Irinotecan + Temozolomide Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Completed
NCT00983398 Phase Ib/II Pegfilgrastim Filgrastim Carboplatin + Melphalan Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Suspended
NCT01217437 Phase II Irinotecan + Temozolomide Bevacizumab + Irinotecan + Temozolomide Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Active, not recruiting
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed
NCT01356290 Phase II Thalidomide Fenofibrate Etoposide Bevacizumab Celecoxib Cyclophosphamide + Cytarabine Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT) Recruiting
NCT01878617 Phase II Vismodegib Cisplatin + Cyclophosphamide + Vincristine Sulfate Gemcitabine + Pemetrexed Disodium A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
NCT01999270 Phase I Bevacizumab + Irinotecan Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors Completed
NCT02040376 Phase III Metformin Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma Completed
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Recruiting
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Active, not recruiting
NCT02332889 Phase Ib/II Decitabine Poly ICLC Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Terminated
NCT02372006 Phase Ib/II Afatinib Trial of Afatinib in Pediatric Tumours Active, not recruiting
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting
NCT02458339 Phase I Methotrexate Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors Completed
NCT02472392 Phase I Fludarabine Cyclophosphamide Melphalan Busulfan anti-thymocyte globulin Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma Completed
NCT02502708 Phase I Indoximod Temozolomide Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors Completed
NCT02644291 Phase I Mebendazole Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Recruiting
NCT02748135 Phase Ib/II TB-403 A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma Recruiting
NCT03130959 Phase II Ipilimumab + Nivolumab Nivolumab An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Active, not recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting
NCT03213678 Phase II LY3023414 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03387020 Phase I Ribociclib Everolimus + Ribociclib Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Completed
NCT03434262 Phase I Filgrastim + Gemcitabine + Pegfilgrastim + Ribociclib Trametinib Sonidegib Ribociclib Ribociclib + Trametinib Ribociclib + Sonidegib Molecularly-Driven Doublet Therapy for Recurrent CNS Malignant Neoplasms Recruiting
NCT03581240 Expanded access Eflornithine An Intermediate Expanded Use Trial of DFMO Available
NCT03598244 Phase I Savolitinib Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors Recruiting
NCT03652545 Phase I MultiTAA-specific T cells Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND) Recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03709680 Phase I Irinotecan + Palbociclib + Temozolomide Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Recruiting
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Recruiting
NCT03893487 Phase I CUDC-907 Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) Recruiting
NCT03904862 Phase Ib/II Silmitasertib Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Recruiting
NCT04023669 Phase I Filgrastim Pegfilgrastim Cyclophosphamide + Prexasertib Gemcitabine + Prexasertib Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Recruiting
NCT04049669 Phase II Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Recruiting
NCT04315064 Phase I MTX110 Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma Recruiting